The Efficacy of Diquafosol Ophthalmic Solution in Non-Sjögren and Sjögren Syndrome Dry Eye Patients Unresponsive to Artificial Tear.
This study evaluates the efficacy of 3% diquafosol tetrasodium ophthalmic solution in Sjögren's syndrome (SS) and non-SS dry eye patients unresponsive to conventional artificial tear.



This retrospective study included 38 dry eye patients (11 with SS and 27 with non-SS) who were treated with 3% diquafosol due to lack of response to artificial tear treatment for more than 3 months. Signs such as tear film break-up time (TBUT), Schirmer-I test, and total ocular staining score (OSS), which consisted of corneal OSS and conjunctival OSS, were evaluated at baseline and the first visit after treatment. Symptoms were quantified using visual analog scale (VAS) and ocular surface disease index (OSDI) scores. Changes of parameters after treatment in all the patients and differences of changes in SS and non-SS were evaluated.



In total population, total OSS and corneal OSS improved average 6 weeks after diquafosol treatment (all P < 0.05, paired t-test), although conjunctival OSS had no improvement. TBUT increased after treatment (P = 0.036), while Schirmer-I test, OSDI, and VAS showed no improvement. With respect to comparisons, total and corneal OSS improved in non-SS patients and TBUT improved in SS patients (all P < 0.05).



Three percent diquafosol tetrasodium treatment could be considered as an additive or substitute treatment when artificial tear treatment is insufficient, as it improved OSS and TBUT. This study also demonstrated that diquafosol treatment is beneficial for TBUT improvement in SS, while it is beneficial for OSS improvement in non-SS dry eye patients.
1 Department of Ophthalmology, Seoul National University Bundang Hospital , Seongnam, Republic of Korea.
Hyun Sun
HS
Jeon
1 Department of Ophthalmology, Seoul National University Bundang Hospital , Seongnam, Republic of Korea.|2 Department of Ophthalmology, Seoul National University College of Medicine , Seoul, Republic of Korea.
Joon Young
JY
Hyon
D000328:Adult; D000368:Aged; D015352:Dry Eye Syndromes / Q000175:diagnosis / Q000188:drug therapy*; D005260:Female; D006801:Humans; D065346:Lubricant Eye Drops / Q000008:administration & dosage / Q000737:chemistry*; D008297:Male; D008875:Middle Aged; D009883:Ophthalmic Solutions / Q000008:administration & dosage / Q000627:therapeutic use*; D011122:Polyphosphates / Q000008:administration & dosage / Q000627:therapeutic use*; D012189:Retrospective Studies; D012859:Sjogren's Syndrome / Q000175:diagnosis / Q000188:drug therapy*; D014500:Uracil Nucleotides / Q000008:administration & dosage / Q000627:therapeutic use*
D065346:Lubricant Eye Drops; D009883:Ophthalmic Solutions; D011122:Polyphosphates; D014500:Uracil Nucleotides; C403315:diquafosol